Advertisements

Estro-Pause (+Norethisterone)

Quick links to important sections

Estro-Pause (+Norethisterone)

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Estro-Pause (+Norethisterone)

Property Description
Active Ingredients Estradiol, Norethisterone
Pharmacological Class Hormone Replacement Therapy (HRT)
Form Oral Tablet (often film-coated), Transdermal Patch
Origin Semi-synthetic/Derived (Combines bio-identical and synthetic hormones)
Type Fixed-dose Combination Drug

What Type of Medicine is Estro-Pause (+Norethisterone)?

Estro-Pause (+Norethisterone) is a prescription-only combined hormonal preparation classified as Hormone Replacement Therapy (HRT), which falls within the Estrogen and Progestin combination pharmacological class. It is supplied as a fixed-dose combination drug intended for systemic administration, typically found in the dosage form of an Oral Tablet that can be film-coated. The combination of Estradiol and Norethisterone is a clinically recognized standard for hormone restoration in postmenopausal care, with analogous formulations including products such as Activella and Amabelz.

Its classification as a combined HRT distinguishes it from single-agent estrogen therapies and is designed specifically to address a broad spectrum of symptoms resulting from natural hormone deficiency.


What is the Composition of Estradiol and Norethisterone?

The medication is composed of two primary active ingredients: the estrogen hormone Estradiol and the progestin hormone Norethisterone. Estradiol serves as the bio-identical estrogen, meaning its structure is equivalent to the body’s primary estrogen. Conversely, Norethisterone (often as norethindrone acetate) is a synthetic derivative of the progestin class.

These two sex hormones are formulated together in a single dosage unit. The inclusion of the progestin ensures that both the necessary hormone replacement action of the Estradiol and the protective action of the Norethisterone are maintained simultaneously.


Why is Estradiol Combined with Norethisterone?

Estradiol is combined with Norethisterone primarily to achieve hormone restoration while ensuring uterine lining protection. The general therapeutic purpose is to safely compensate for the decline in natural hormones in postmenopausal women.

The fundamental rationale for this fixed-dose combination is safety: the progestin component, Norethisterone, is a mandatory protective measure to oppose the stimulatory effects of the Estradiol on the endometrium. This opposition significantly reduces the risk of endometrial hyperplasia and cancer in women who retain a uterus, establishing the core functional benefit of this combined therapy.

Regulatory References

  1. Estradiol/Norethindrone (HRT)
Advertisements

What side effects are possible with Estro-Pause (+Norethisterone)?

Possible Side Effects and Safety Information

The safety profile for this combined Hormone Replacement Therapy (HRT), which contains Estradiol and Norethisterone, is classified by governmental regulatory authorities based on the incidence and nature of adverse events observed in clinical trials.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by the body system affected and frequency. Very common reactions (ge 1/10 in some regulatory documents) may include Headache and Breast tenderness. Common reactions (ge 1/100 to < 1/10) often affect the gastrointestinal system (such as Nausea or Abdominal pain) and may include events like Dizziness, Weight increase, and Vaginal haemorrhage or spotting. The occurrence of vaginal bleeding is officially noted to be common during the initial months of treatment.

Serious Systemic Safety Considerations

Official labeling documents significant risks, often detailed in Boxed Warnings in the U.S. Prescribing Information. Estrogen-plus-progestin therapy is associated with increased risks of Serious Adverse Reactions, including Vascular Events such as Stroke, Myocardial Infarction (MI), Deep Vein Thrombosis (DVT), and Pulmonary Embolism (PE). Furthermore, an increased risk of Breast Cancer is reported with combined HRT use, and a heightened risk of probable dementia is noted for postmenopausal women aged 65 years or older.

Safety-Related Restrictions

The medicine is formally Contraindicated in individuals with conditions such as a history of DVT, PE, Stroke, or MI; known or suspected Breast Cancer; and active or history of severe hepatic disease. The inclusion of Norethisterone is a safety requirement for women who retain a uterus to reduce the risk of endometrial hyperplasia and cancer.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

Overdose Scope

Category Official Regulatory Statement
Documented Manifestations Acute overdose may present with symptoms including nausea, vomiting, breast tenderness, headache, and drowsiness. Excessive vaginal bleeding (withdrawal bleeding) is a documented manifestation that may occur a few days following the over-exposure.
Emergency Actions Seek immediate medical attention for any suspected overdose event. Contact emergency services immediately if clinical signs are severe or rapidly worsening.
Management Management must be entirely symptomatic and supportive. Regulatory labels confirm that no specific antidote is known for this combination of active ingredients.
Population-Specific Note Ingestion by pediatric patients may lead to documented symptoms such as nausea, vomiting, and the potential for withdrawal bleeding in girls.

Overdose Classification

The official product labeling classifies acute overdose presentation as a severe exaggeration of known adverse effects. Severe, immediate life-threatening outcomes are not consistently listed as direct acute manifestations of over-exposure alone. The required emergency response is strictly defined as supportive care and hospital monitoring, as determined by government regulatory bodies.

Resulting Overdose Structure

Official regulatory statements clarify that hospital monitoring may be required for observation and management of all documented clinical manifestations. The profile strictly dictates that any individual suspecting an overdose must immediately contact professional medical services for an evaluation of the condition and to initiate appropriate symptomatic support.

Advertisements

Therapeutic Uses of Estro-Pause (+Norethisterone)

Estro-Pause, a form of continuous combined hormone replacement therapy (HRT), is applied across domains where additional symptomatic support is needed to address symptoms associated with acute or episodic changes of the menopause. This combination therapy is commonly used to help with symptoms that interfere with daily functioning, providing support that helps ease the overall symptom burden. As a combined HRT, it:

“supports the patient during difficult episodes by easing distress.”

The primary uses include managing hot flushes (vasomotor symptoms), night sweats, mood swings, and symptoms related to inflammatory or irritative states such as vaginal dryness or atrophy. Additionally, this therapy may be part of symptomatic management for the prevention of postmenopausal osteoporosis in women at high risk of fracture. The combination may be relevant when supportive symptom management is appropriate for women who still have a uterus, as the progestogen component assists with maintaining functional stability.

Quick Fact: Relief for Symptoms that interfere with daily functioning

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Estro-Pause (+Norethisterone)?

Official regulatory documentation defines strict eligibility rules for the use of Estro-Pause (+Norethisterone), a combined Hormone Replacement Therapy (HRT).

This medication is specifically approved for postmenopausal adult women who retain a uterus.


Absolute Contraindications

The medicine must not be used by women with the following conditions, as they are considered absolute contraindications:

Classification Prohibited Conditions
Thromboembolic History Active or history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, or Myocardial Infarction (MI).
Neoplasia Known or suspected breast cancer or other estrogen-dependent neoplasia.
Other Undiagnosed abnormal genital bleeding, severe hepatic impairment, or known thrombophilic disorders.

Population-Specific Restrictions

Population Regulatory Status
Pregnancy Contraindicated (not to be used).
Lactation Not recommended.
Pediatric Use Not indicated; use is not established.
Geriatric Use Caution is required for women 65 years and older due to an officially documented increased risk of probable dementia; the drug is not approved for dementia prevention.
Sole-Purpose Use Limited for use solely for osteoporosis prevention or vulvar/vaginal atrophy; other treatments must be considered first.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details specific interactions for Estradiol and Norethisterone based on metabolic enzyme activity and formal prohibitions.


Documented Interaction Patterns

Classification Official Regulatory Statement
Contraindicated Combinations The combination is formally prohibited with certain Hepatitis C combination therapies (e.g., Ombitasvir, Paritaprevir, Ritonavir pm Dasabuvir) due to the risk of significant ALT (liver enzyme) elevation. Co-administration with Acitretin is also restricted.
Metabolic Interactions Strong CYP3A4 Inducers (e.g., Apalutamide) may decrease the exposure of the Norethindrone component. Conversely, strong CYP3A4 Inhibitors may increase its exposure.
Pharmacodynamic Conflicts The Norethindrone component may decrease the therapeutic effect of Antidiabetic Agents due to its potential to impair glucose tolerance. Estradiol also acts as a pharmacodynamic antagonist to Aromatase Inhibitors.

Substance and Population Modifiers

Modifying Substance / Condition Documented Interaction Outcome
Alcohol / Grapefruit Juice Acute alcohol ingestion and Grapefruit Juice consumption are documented to increase circulating Estradiol levels by altering hormone metabolism.
Tobacco Use Co-administration with Tobacco (cigarette smoking) is associated with a significantly increased risk of serious cardiovascular events in women over 35 years of age.

The established structure of the interaction profile defines mandatory prohibitions and specifies the metabolic and physiological conflicts that constrain safe co-administration, as recorded in official government labeling.

Advertisements

Mechanism of Action

Activation of Nuclear Steroid Receptors

The estradiol component acts as an agonist by selectively binding to and activating Estrogen Receptors (ERs), while the norethisterone component acts on Progesterone Receptors (PRs). This process engages the classic genomic pathway, where the activated receptor complexes enter the cell nucleus to modulate the transcription of target genes. This central mechanism contributes to the diverse range of physiological consequences, modulating the activity of estrogen-responsive systems, including those influencing skeletal tissue maintenance, central nervous system signaling, and urogenital tract tissue structure.

Balanced Endometrial Regulation

In the uterus, estradiol promotes endometrial proliferation by stimulating ERs. The norethisterone component, acting via PRs, induces a secretory transformation, mediating a shift from the proliferative state. This sequential, balanced modulation of cellular growth is vital for inducing a different pattern of cellular activity in the endometrium relative to the estrogenic stimulus.

Systemic Signaling Stabilization

Estrogen receptor activation within the hypothalamus influences the neural pathways that govern thermoregulation and vasomotor stability. The resulting modulation of these signaling patterns contributes to the regulated activity of vasomotor centers, which in turn influences peripheral vascular tone.

Advertisements

Dosage and Administration Information

The administration of Estro-Pause (+Norethisterone) is governed by specific guidelines that establish a standardized, fixed-dose usage pattern. The medication is delivered via the oral route as a film-coated tablet. It is classified as a continuous combined hormone therapy, meaning one tablet is taken once daily without a scheduled break in the cycle, which is a key procedural requirement for this regimen.

Official Dosing and Timing

Fixed-dose strengths are established in prescribing information, often including 1 mg Estradiol combined with 0.5 mg Norethisterone Acetate, or the lower strength of 0.5 mg Estradiol with 0.1 mg Norethisterone Acetate. Clinical guidance dictates using the lowest effective dose for the shortest duration, with a clinical re-evaluation of the necessity for continued therapy occurring periodically.

For consistency of circulating hormone levels, the tablet should be taken at the same time each day, and the administration can occur with or without food.

Procedural Instructions

If a dose is forgotten, the general instruction is to take the missed tablet as soon as it is remembered. However, if it is almost time for the next scheduled dose, protocols advise skipping the missed dose and continuing with the regular schedule. Furthermore, this medication is not indicated for use in individuals under the age of 18, as its safety and efficacy have not been established in the pediatric population.

Advertisements

Recent Clinical Evidence

Estro-Pause (+Norethisterone): Recent Clinical Evidence


1. Evidence for the Management of Vasomotor Symptoms

The research for Estro-Pause (+Norethisterone), a combined hormone therapy, is primarily based on Randomized Controlled Trials (RCTs). These short-term studies explored how symptoms change over time in postmenopausal women with an intact uterus. Research examined physical discomfort, specifically measuring the frequency and severity of hot flushes and night sweats, and utilized patient-reported outcomes. Studies report on changes measured during the observation period, including shifts in symptom intensity.

2. Research Evidence for Bone Health and Osteoporosis Prevention

Evidence for the use of this combined therapy in the context of postmenopausal osteoporosis has been evaluated in controlled trials and observational settings. These studies included women defined as being at high risk of bone loss or fracture. Research was studied for conditions marked by functional limitations and examined Bone Mineral Density (BMD) at the hip and spine. Longer-term evidence also included tracking the incidence of non-vertebral and hip fractures.

Controlled trials consistently reported how symptoms evolved in the observed populations, noting measurements of increases in BMD. Evidence from broader analyses described patterns related to the incidence of non-vertebral and hip fractures. Most research highlights changes measured over moderate-term periods, typically ranging from three to five years.

3. Scientific Gaps and Areas for Future Research

Evidence highlights what is known—and what is still uncertain—about the combined therapy. Key limitations consistently noted in the research landscape include limited information for long-term outcomes, as most large-scale RCTs have follow-up durations restricted to a few years. Data for certain groups remain insufficient, such as those who are considered older adults (e.g., over age 65) when starting the therapy. Furthermore, comparative evidence is lacking in some areas, such as detailed studies comparing the long-term effectiveness of this specific combined oral therapy against localized treatments for genitourinary symptoms. Study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References Menopause: identification and management (NG23) (NICE Guideline)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Estro-Pause (+Norethisterone) (FAQ)


Q: What is Estro-Pause (+Norethisterone) actually used for?

The official product information describes this medicine as indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats. It is also indicated for the prevention of postmenopausal osteoporosis in certain populations.


Q: Will Estro-Pause help with night sweats?

Studies have examined how this therapy affects the frequency and severity of vasomotor symptoms, including night sweats. Evidence from studies indicates that these symptoms are typically among those for which the medication is intended.


Q: Can Estro-Pause be taken long-term?

Official regulatory guidance advises that treatment should always be used at the lowest effective dose for the shortest duration needed. A clinical re-evaluation of the necessity for continued use is advised to occur periodically.


Q: Can Estro-Pause be used if I have a history of breast cancer in my family?

A personal history of known or suspected breast cancer is an absolute contraindication, meaning the medicine must not be used. While a family history of breast cancer is not an absolute prohibition, official documents list it as a risk factor. A thorough health assessment may be conducted to evaluate this risk before treatment is considered.


Q: Can I drink alcohol while taking Estro-Pause?

Official documentation notes that the acute ingestion of alcohol is documented to potentially cause an increase in the level of circulating estradiol (the estrogen component) in the body. This is due to how the body processes the hormone.


Q: What happens if I take Estro-Pause with an herbal supplement like St. John's Wort?

Official product labeling warns that certain substances classified as strong CYP3A4 inducers may decrease the exposure of the norethindrone component. Some common herbal supplements, such as St. John’s Wort, may fall into this category.


Q: Can Estro-Pause be used by women who have had a hysterectomy?

The combination of Estradiol and Norethisterone is generally indicated for women who retain a uterus. This is because the progestin component is a mandatory safety measure to protect the uterine lining. Women who have had a hysterectomy are generally not candidates for this combined therapy and may require estrogen-only therapy instead.


Q: Is there a maximum age limit for using Estro-Pause?

Official regulatory documents specify caution for women 65 years of age or older due to an officially documented increased risk of probable dementia observed in this age group. Official guidance highlights that the medicine is not approved for the prevention of dementia.


Q: Is there strong clinical evidence showing Estro-Pause helps with hot flashes?

The evidence supporting this therapy comes from controlled trials that specifically examined the frequency and severity of hot flushes in postmenopausal women. The studies report on the measured shifts in symptom intensity observed during the trials.


Q: Will Estro-Pause make my period come back if I'm already menopausal?

According to official product information, vaginal bleeding or spotting is listed as a common adverse reaction, particularly during the first months of treatment. This bleeding is typically not classified as a return to a regular menstrual period.


Q: Why is Estro-Pause used as a continuous treatment?

This medicine is classified as a continuous combined therapy, meaning one tablet is taken every day without a scheduled break. This continuous regimen is typically used to deliver a steady level of hormones, which often results in the avoidance of scheduled withdrawal bleeding.


Q: Are there any food restrictions when using Estro-Pause?

You can generally take the tablet with or without food. However, official regulatory documents specifically note an interaction with Grapefruit Juice, stating that its consumption is documented to increase circulating Estradiol levels in the body.


Q: What kind of monitoring or check-ups are typically needed when using Estro-Pause?

Regulatory guidance advises a clinical re-evaluation of the need for continued therapy should occur periodically. Official documents may also recommend certain check-ups, such as regular breast examinations and blood pressure monitoring, while using the medicine.


Q: What should I know about taking Estro-Pause if I have diabetes?

Official labeling states that the Norethindrone component of the drug may potentially decrease the therapeutic effect of antidiabetic agents. The effect is related to the drug's potential to influence the body's glucose tolerance.


Q: What are the risks of using Estro-Pause for longer than five years?

Longer duration of combined HRT use is officially reported to be associated with increased risks of serious adverse reactions, including breast cancer and certain vascular events. Regulatory guidance advises using the therapy for the shortest duration necessary.


Q: Is Estro-Pause safe to use if I have high blood pressure?

While pre-existing hypertension (high blood pressure) is not listed as an absolute contraindication, official regulatory labeling often requires caution. This is due to the association between HRT and certain vascular risks, and close monitoring of blood pressure may be necessary.


Q: Do I need to stop taking Estro-Pause before surgery?

Regulatory documents indicate that the therapy is advised to be discontinued for at least 4 to 6 weeks prior to major surgery that is associated with an increased risk of blood clots. It is also advised to stop during periods of prolonged immobilization.


Q: Does Estro-Pause affect cholesterol levels?

Official product documents often include information describing the effect of the estrogen component on metabolic processes. Changes in lipid profiles, which include cholesterol levels, are sometimes noted in the pharmacological section of the labeling.


Q: Why do official documents mention a link between Estro-Pause and gallbladder issues?

Official regulatory documentation states that the use of this type of therapy is documented to be associated with an increased risk of gallbladder disease.


Q: Can Estro-Pause affect the results of blood tests?

Estrogen use is documented in official labeling to affect the results of certain laboratory tests. These effects may include changes in coagulation parameters (factors that relate to blood clotting) and levels of thyroid-binding globulin.


Q: Is it normal to feel bloated when starting Estro-Pause?

Common adverse reactions affecting the gastrointestinal system include abdominal pain and nausea. While 'bloating' may not be explicitly listed, regulatory documents sometimes note a related symptom called abdominal distension.


Q: Does Estro-Pause affect hair loss or hair growth?

Official product labeling sometimes lists changes in hair growth or hair loss (medically termed alopecia) under less common adverse reactions for this class of medicine.


Q: Can Estro-Pause affect my sleep quality?

While the therapy is often used to address symptoms like night sweats that disrupt sleep, official documents may also list specific sleep disturbances, such as insomnia, as a possible adverse reaction.


Q: What is meant by the term 'contraindication' for Estro-Pause?

In medical terms, a contraindication is a specific reason or circumstance where the medicine must not be used. Patient information materials define it as a condition where the potential harm of using the drug outweighs any potential benefit.


Q: Why is Estro-Pause sometimes linked to changes in vision?

Official product information documents an association between this class of medicine and certain vascular events. These risks include the potential for developing retinal vascular thrombosis, which is a blood clot that can form in the blood vessels of the eye and may affect vision.


Q: Are there specific symptoms that require immediate medical attention while using Estro-Pause?

Official patient information materials list specific signs associated with serious adverse reactions that require prompt medical review.


Q: Does Estro-Pause contain lactose or any other common allergens?

The regulatory documents, such as the full prescribing information, list all the inactive ingredients (excipients) used in the tablet formulation. These lists are used to identify common components like lactose or other materials that may be relevant to allergy concerns.


Q: Does taking Estro-Pause affect fertility?

This therapy is contraindicated in pregnancy and is generally not indicated for women who are trying to conceive or women who are still in the reproductive age group. This medicine is specifically approved for use only in postmenopausal women.

Advertisements

How should Estro-Pause (+Norethisterone) be stored and disposed of?

How to Store and Dispose of Estro-Pause (+Norethisterone)?

Storage of this combined hormone replacement therapy must adhere strictly to regulatory requirements to ensure product stability.


Official Storage Conditions

Requirement Specific Condition
Temperature Range Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Environmental Protection Protect the tablets from moisture, light, and excessive heat. Do not freeze the medicine.
Container Rules Keep the product in its original container and ensure the container is tightly closed.
Safety Constraint Store the medicine out of the sight and reach of children and pets.

Disposal Requirements

Do not dispose of unused or expired Estro-Pause (+Norethisterone) via household waste or by flushing it into wastewater. Regulatory guidelines mandate that unused medicinal products must be returned to a pharmacy or discarded according to specific local pharmaceutical waste procedures. Do not use the medicine past the expiration date on the package.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estro-Pause (+Norethisterone) found in:

A-Z Index: